BDUK-Tx develops a groundbreaking next generation loco-regional therapy for the $11B global fast-growing liver cancer market, a disease with low-efficacy and intolerable therapy.

Our product, a novel combination of 3 clinically known components, is superior to current therapies with a de-risked profile. BDUK leadership is supported by world leading medical, scientific and business experts. BDUK is raising $4m to reach our 1st significant valuation inflection point.